Completed PHASE4 INTERVENTIONAL 3-arm NCT02189603

Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）

Evaluation of Safety and Immunogenicity of Recombinant (E. Coli) Hepatitis E Vaccine（Hecolin®） in Seniors Aged Over 65 Years

Sponsor: Jun Zhang

Conditions Hepatitis E

Interventions Recombinant (E. Coli) Hepatitis E Vaccine

Updated 8 times since 2017 Last updated: Aug 15, 2018 Started: Jun 30, 2014 Primary completion: Dec 7, 2015 Completion: Dec 7, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02189603, this PHASE4 trial focuses on Hepatitis E and remains completed. Sponsored by Jun Zhang, it has been updated 8 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Feb 2024 — Jul 2024 [monthly]

Completed PHASE4
Jan 2024 — Feb 2024 [monthly]

Completed PHASE4
Jan 2021 — Jan 2024 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Sep 2018 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jun 2018 — Sep 2018 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jun Zhang
Xiamen Center for Disease Control and Prevention
Xiamen Innovax Biotech Co., Ltd

Data source: Xiamen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xiamen, China